Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data
SAS, the leader in business analytics, announced that Shire, the global specialty biopharmaceutical company, has selected SAS® Drug Development as the platform for its clinical trials data.
generic viagra online
Two New Studies On Circadian Rhythms
Dartmouth Medical School geneticists have made new inroads into understanding the regulatory circuitry of the biological clock that synchronizes the ebb and flow of daily activities, according to two studies published May 15.
News of the day
Medicare Reimbursement Issues Enter Health Reform Debate
New legislation introduced yesterday would attempt to shift Medicare reimbursement policy to reward patient health outcomes, rather than the volume of services provided, MinnPost, a nonprofit online news organization, reports. "We need to be sure to keep score," said Sen. Amy Klobuchar, D-Minn., who introduced the bill, according to MinnPost. "That means measuring outcomes and rewarding providers that deliver quality results."
Sexual Health

ImmunoVaccine Technologies Partners With FIT Biotech To Advance A Therapeutic HIV Vaccine

ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based , clinical stage company that develops DNA vaccines. This research will formulate FIT Biotech"s GTU(R) MultiHIV DNA plasmid with IVT"s DepoVax(TM) vaccine delivery system to advance a therapeutic HIV vaccine. "DepoVax(TM) will act as a vector to deliver FIT Biotech"s GTU(R) MultiHIV DNA vaccine and our goal is to develop a more sophisticated and efficient HIV vaccine candidate," commented Dr. Marc Mansour, Vice President R&D at IVT. The development of an HIV vaccine is complicated by the ability of the virus to mutate rapidly. FIT Biotech has addressed this challenge by designing a synthetic DNA plasmid, known as GTU(R) MultiHIV that covers the antigenic variability within HIV strains. GTU(R) MultiHIV and is comprised of the multi-epitope/multivalent HIV antigens. As FIT Biotech"s lead vaccine candidate, GTU(R) MultiHIV has the potential to trigger an immune response that slows the progression of HIV in infected individuals. IVT"s pre-clinical research demonstrates that DepoVax(TM) effectively delivers DNA plasmids into draining lymph nodes with as little as one dose. The DepoVax(TM) platform uses liposomes to encapsulate a target antigen, like GTU(R) MultiHIV, and adjuvant. DepoVax(TM) also relies on a hydrophobic carrier to create a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity. This pre-clinical research partnership will combine the complementary technologies of DepoVax(TM) and GTU(R) MultiHIV. Both IVT and FIT Biotech will examine the novel vaccine"s capabilities of inducing cell-mediated and humoral immunity against HIV virus. "By testing DepoVax(TM) in combination with GTU(R) MultiHIV plasmid, we are working towards developing a superior vaccine candidate for therapeutic use against HIV and AIDS," said Kalevi Reijonen, President and CEO at FIT Biotech. The WHO reports that 33 million people are living with HIV and the epidemic is rapidly expanding with 2.7 million people newly infected in 2007. Nearly all of them will develop AIDS-related complications, creating an urgent need for effective HIV therapeutic vaccines. Therapeutic vaccination offers the most hope for HIV infected individuals because it maintains a low viral load and has the potential to modify the course of the infection and its progression towards the AIDS disease. ImmunoVaccine Technologies Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009